ImmuCell director awarded 11,933 stock options

ImmuCell Corp director David Scott Tomsche received a grant of stock options as part of his compensation.

Rhea-AI Filing Summary

ImmuCell Corp director David Scott Tomsche received a grant of stock options as part of his compensation. He was awarded 11,933 non-qualified stock options to buy ImmuCell common stock at an exercise price of $7.60 per share, expiring on April 15, 2036.

The options vest over time: 3,977 become exercisable on April 15, 2027, another 3,977 on April 15, 2028, and 3,979 on April 15, 2029. This is a compensation-related award, not an open-market purchase or sale of shares.

Insider Trade Summary

Grant/Award: 11,933 shares

Grant/Award 1 txn

Insider Tomsche David Scott

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non Qualified Stock Options (Right to buy)	11,933	$0.00	$0.00

Holdings After Transaction: Non Qualified Stock Options (Right to buy) — 11,933 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests as follows: 3,977 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 shares becoming exercisable on April 15, 2029.

Key Figures

Options granted: 11,933 options Exercise price: $7.60 per share Expiration date: April 15, 2036 +4 more

7 metrics

Options granted 11,933 options Non-qualified stock options awarded to director

Exercise price $7.60 per share Conversion or exercise price of granted options

Expiration date April 15, 2036 Options expire on this date

Post-transaction derivative holdings 11,933 options Total options held from this grant after transaction

First vesting tranche 3,977 options Become exercisable on April 15, 2027

Second vesting tranche 3,977 options Become exercisable on April 15, 2028

Third vesting tranche 3,979 options Become exercisable on April 15, 2029

Key Terms

Non Qualified Stock Options, exercise price, expiration date, vests, +1 more

5 terms

Non Qualified Stock Options financial

"security_title: "Non Qualified Stock Options (Right to buy)""

exercise price financial

"conversion_or_exercise_price: "7.6000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-04-15T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vests financial

"The stock option vests as follows: 3,977 shares becoming exercisable..."

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ImmuCell (ICCC) director David Scott Tomsche report in this Form 4?

He reported receiving 11,933 non-qualified stock options as a compensation award. These options allow him to buy ImmuCell common stock at a fixed $7.60 exercise price, subject to a multi-year vesting schedule and an expiration date in 2036.

Is the ImmuCell (ICCC) Form 4 transaction a stock purchase or sale?

The filing reports an option grant, not a market purchase or sale. Tomsche received 11,933 non-qualified stock options as a grant, with no cash paid and no shares traded in the market at the time of this Form 4 transaction.

What are the key terms of David Scott Tomsche’s ImmuCell (ICCC) stock options?

The grant covers 11,933 non-qualified stock options with a $7.60 exercise price and an expiration on April 15, 2036. The options relate to ImmuCell common stock and become exercisable only as they vest over the specified future dates.

How do the ImmuCell (ICCC) options granted to David Scott Tomsche vest over time?

The options vest in three tranches. 3,977 options become exercisable on April 15, 2027, another 3,977 on April 15, 2028, and the remaining 3,979 on April 15, 2029. He can exercise only the vested portion after each vesting date.

What is David Scott Tomsche’s position in ImmuCell (ICCC) after this Form 4 grant?

Following the transaction, he holds 11,933 stock options from this grant. These options are a right to buy ImmuCell common shares at $7.60, with actual share ownership arising only if and when he exercises vested options in the future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/16/2026 - 04:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tomsche David Scott

(Last) (First) (Middle)

C/O IMMUCELL CORPORATION

56 EVERGREEN DRIVE

(Street)

PORTLAND MAINE 04103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUCELL CORP /DE/ [ ICCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non Qualified Stock Options (Right to buy)	$7.6	04/15/2026		A		11,933		(1)	04/15/2036	Common Stock	11,933	$0	11,933	D

Explanation of Responses:

1. The stock option vests as follows: 3,977 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 shares becoming exercisable on April 15, 2029.

Remarks:

The options were granted by the issuer to compensate directors for services on the Issuer's board of directors.

	/s/ Timothy C. Fiori Attorney-in-Fact	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)